Dhootpapeshwar Sarvatobhadra Vati
SKU:
11934
Category: Kidney and Urinary Health Support
Brand: Shree Dhootapapeshwar
HSN Code: 30049011Pack Size: 10 TAB
₹ 2,330.00 Original price was: ₹ 2,330.00.₹ 1,980.50Current price is: ₹ 1,980.50.
17 in stock
52
People watching this product now!
14
Items sold in last hour
Add ₹ 999.00 to cart and get free shipping!
Fast & Reliable Delivery
100% Genuine Product
Secure Payment Options
Dedicated Customer Support
Description
Sarvatobhadraa Vati is an effective treatment for Vrukkavikar (kidney-related disorders). It helps alleviate Mootraghat (urinary obstruction), Mootrashmari (urinary stones), and Mootrakruchchhra (painful urination). This formulation is particularly useful in maintaining urinary health and addressing issues related to kidney and urinary tract.
Indications:
Mootraghat (Urinary obstruction)
Mootrashmari (Urinary stones)
Mootrakruchchhra (Painful urination)
Dosage & Anupan:
1 to 2 tablets, once or twice a day with Gokharu Kadha, Bruhat Varunadi Kadha, lukewarm water, or as per the disease condition.
Reviews (0)
Rated 0 out of 5
0 reviews
Rated 5 out of 5
0
Rated 4 out of 5
0
Rated 3 out of 5
0
Rated 2 out of 5
0
Rated 1 out of 5
0
Be the first to review “Dhootpapeshwar Sarvatobhadra Vati” Cancel reply
Disclaimer:
Product details, including colors and availability, may vary slightly. Always read descriptions carefully before purchase....
Read More
Product details, including colors and availability, may vary slightly. Always read descriptions carefully before purchase. We do not encourage self-medication. Information provided on this site or linked sources is not a substitute for professional medical advice. Please consult a qualified healthcare provider before using any medication, supplement, or booster. A proper medical check-up is essential to determine the correct dosage, frequency, and duration based on individual needs. Returns are subject to our return policy.
Related products
10 CAP
100 TAB
30 TAB
10 CAP
200GM
10 TAB



Reviews
Clear filtersThere are no reviews yet.